This HTML5 document contains 116 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n25http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n17http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/chemspider/
n8http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/chebi/
n6http://linked.opendata.cz/resource/drugbank/company/
n13http://linked.opendata.cz/resource/drugbank/dosage/
n4http://linked.opendata.cz/resource/drugbank/mixture/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/wikipedia/
n30http://bio2rdf.org/drugbank:
n11http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/pharmgkb/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/kegg-compound/
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/bindingdb/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/pubchem-compound/
n29http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n23http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/pubchem-substance/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n9http://linked.opendata.cz/resource/drugbank/medicinal-product/
n7http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/drugbank/
n15http://www.drugs.com/cdi/
n5http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB00748/identifier/national-drug-code-directory/
n27http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00748
rdf:type
n3:Drug
n3:description
Carbinoxamine is a first generation antihistamine that competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many unapproved carbinoxamine-containing preparations contained inappropriate labeling, which promoted unapproved uses (including management of congestion, cough, the common cold, and the use in children under 2 years of age), which can potentially cause serious health risks.
n3:dosage
n13:271B5709-363D-11E5-9242-09173F13E4C5 n13:271B570A-363D-11E5-9242-09173F13E4C5 n13:271B5707-363D-11E5-9242-09173F13E4C5 n13:271B5708-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# BEALE HD, RAWLING FF, FIGLEY KD: Clistin maleate; a clinical appraisal of a new antihistaminic. J Allergy. 1954 Nov;25(6):521-4. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13211145
n3:group
approved
n3:halfLife
10 to 20 hours
n3:indication
For symptomatic relief of seasonal and perennial allergic rhinitis and vasomotor rhinitis, as well as allergic conjunctivitis caused by foods and inhaled allergens. Also for the relief of allergic reactions to blood or plasma, and the symptomatic management of mild, uncomplicated allergic skin manifestations of urticaria and angioedema.
n3:manufacturer
n6:271B5704-363D-11E5-9242-09173F13E4C5 n6:271B5702-363D-11E5-9242-09173F13E4C5 n6:271B5703-363D-11E5-9242-09173F13E4C5 n6:271B5700-363D-11E5-9242-09173F13E4C5 n6:271B5701-363D-11E5-9242-09173F13E4C5 n6:271B56FF-363D-11E5-9242-09173F13E4C5
owl:sameAs
n29:DB00748 n30:DB00748
dcterms:title
Carbinoxamine
adms:identifier
n11:PA164746898 n12:Carbinoxamine n16:3398 n17:2466 n18:50240487 n19:0525-6748-01 n20:DB00748 n21:C06871 n22:2564 n23:46506787
n3:mechanismOfAction
Carbinoxamine competes with free histamine for binding at HA-receptor sites. This antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. Carbinoxamine's anticholinergic action appears to be due to a central antimuscarinic effect, which also may be responsible for its antiemetic effects, although the exact mechanism is unknown.
n3:packager
n6:271B56F9-363D-11E5-9242-09173F13E4C5 n6:271B56FA-363D-11E5-9242-09173F13E4C5 n6:271B56F7-363D-11E5-9242-09173F13E4C5 n6:271B56F8-363D-11E5-9242-09173F13E4C5 n6:271B56F5-363D-11E5-9242-09173F13E4C5 n6:271B56F6-363D-11E5-9242-09173F13E4C5 n6:271B56F3-363D-11E5-9242-09173F13E4C5 n6:271B56F4-363D-11E5-9242-09173F13E4C5 n6:271B56F2-363D-11E5-9242-09173F13E4C5 n6:271B56FB-363D-11E5-9242-09173F13E4C5 n6:271B56FC-363D-11E5-9242-09173F13E4C5 n6:271B56FE-363D-11E5-9242-09173F13E4C5 n6:271B56FD-363D-11E5-9242-09173F13E4C5
n3:synonym
{2-[(4-chloro-phenyl)-pyridin-2-yl-methoxy]-ethyl}-dimethyl-amine Carbinoxamin Carbinoxamine base Paracarbinoxamine 2-(P-chloro-alpha-(2-(dimethylamino)Ethoxy)benzyl)pyridine Carbinoxamine Carbinoxamina (+-)-Carbinoxamine Carbinoxaminum
n3:mixture
n4:271B56E3-363D-11E5-9242-09173F13E4C5 n4:271B56E0-363D-11E5-9242-09173F13E4C5 n4:271B56E1-363D-11E5-9242-09173F13E4C5 n4:271B56E6-363D-11E5-9242-09173F13E4C5 n4:271B56E7-363D-11E5-9242-09173F13E4C5 n4:271B56E4-363D-11E5-9242-09173F13E4C5 n4:271B56E5-363D-11E5-9242-09173F13E4C5 n4:271B56EA-363D-11E5-9242-09173F13E4C5 n4:271B56EB-363D-11E5-9242-09173F13E4C5 n4:271B56E8-363D-11E5-9242-09173F13E4C5 n4:271B56E9-363D-11E5-9242-09173F13E4C5 n4:271B56EE-363D-11E5-9242-09173F13E4C5 n4:271B56EF-363D-11E5-9242-09173F13E4C5 n4:271B56EC-363D-11E5-9242-09173F13E4C5 n4:271B56ED-363D-11E5-9242-09173F13E4C5 n4:271B56F0-363D-11E5-9242-09173F13E4C5 n4:271B56F1-363D-11E5-9242-09173F13E4C5 n4:271B56DA-363D-11E5-9242-09173F13E4C5 n4:271B56DB-363D-11E5-9242-09173F13E4C5 n4:271B56D9-363D-11E5-9242-09173F13E4C5 n4:271B56DE-363D-11E5-9242-09173F13E4C5 n4:271B56DF-363D-11E5-9242-09173F13E4C5 n4:271B56DC-363D-11E5-9242-09173F13E4C5 n4:271B56DD-363D-11E5-9242-09173F13E4C5 n4:271B56E2-363D-11E5-9242-09173F13E4C5
n3:salt
n3:synthesisReference
Tilford. C.H. and Shelton, R.S.; U.S. Patent 2,606,195;August 5,1952; assigned to The Wm.S. Merrell Company. Swain, A.P.; U.S. Patent 2800,485; July 23,1957; assigned to McNeil Laboratories, Inc.
n7:hasConcept
n8:M0045779
foaf:page
n15:carbinoxamine-maleate.html n25:rondecsyr.htm
n3:IUPAC-Name
n5:271B570F-363D-11E5-9242-09173F13E4C5
n3:InChI
n5:271B5715-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n5:271B5714-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n5:271B5711-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n5:271B5712-363D-11E5-9242-09173F13E4C5
n3:SMILES
n5:271B5713-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n5:271B570D-363D-11E5-9242-09173F13E4C5
n3:logP
n5:271B570B-363D-11E5-9242-09173F13E4C5 n5:271B5726-363D-11E5-9242-09173F13E4C5 n5:271B570E-363D-11E5-9242-09173F13E4C5
n3:logS
n5:271B570C-363D-11E5-9242-09173F13E4C5
n26:hasATCCode
n27:R06AA08
n3:H-Bond-Acceptor-Count
n5:271B571B-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n5:271B571C-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n5:271B5716-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n5:271B5717-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n5:271B5719-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n5:271B5718-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n5:271B571A-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
486-16-8
n3:category
n3:containedIn
n9:271B5705-363D-11E5-9242-09173F13E4C5 n9:271B5706-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n5:271B5720-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n5:271B5725-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n5:271B5722-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n5:271B5723-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n5:271B5724-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n5:271B571F-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n5:271B571E-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n5:271B5721-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n5:271B5710-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n5:271B571D-363D-11E5-9242-09173F13E4C5